Eisai’s investigational Alzheimer’s drug lecanemab appeared to erase amyloid plaques in 4/5 of trial participants and slow cognitive decline for people with early-stage Alzheimer’s…
This week, on the heels of Aduhelm’s FDA approval, the agency granted breakthrough status to two more prospective new Alzheimer’s treatments, Eli Lilly &…
With the #MoreTime campaign, the Alzheimer’s Association has gone all in on aducanumab, the controversial new Alzheimer’s drug produced by Biogen and Eisai. With…
Many people think of virtual and augmented reality as popular forms of entertainment — but these technologies are becoming more central to healthcare, now…